Christopher Pierce, M.B.A.
Executive Vice President and Chief of Business Operations
Christopher Pierce, M.B.A. joined Prelude Therapeutics in 2020 as Executive Vice President and Chief of Business Operations. He previously served as Vice President and Head of Commercial at Loxo Oncology, where he built and oversaw the company’s commercial organization. Mr. Pierce led the launch of Vitrakvi® (larotrectinib) in a co-promote partnership with Bayer, as well as all commercialization activities for Retevmo® (selpercatinib / LOXO-292). Prior to joining Loxo, Mr. Pierce held several roles of increasing commercial responsibility at Pfizer Oncology from 2007 to 2017, most recently as Senior Director and Global Commercial Lead of the Hematologic Malignancies Portfolio. While at Pfizer, he led the launch and in-line management of various oncology therapeutics such as Xalkori® (crizotinib), Sutent® (sunitinib), Inlyta® (axitinib), Bosulif® (bosutinib), Mylotarg® (gemtuzumab ozagamicin), and Besponsa® (inotuzumab ozogamicin). From 2004 to 2006, Mr. Pierce worked at Millennium Pharmaceuticals managing market analytics for Velcade® (bortezomib). Before Millennium, Mr. Pierce was a life sciences management strategy consultant. Mr. Pierce received his A.B. degree in Biochemical Sciences from Harvard College and his M.B.A. from the Harvard Business School.